Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00716976 · OUTCOME

Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy · Source last updated 2023-11-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
4 weeks after the last dose of cisplatin

Analysis population: Data was and never will be collected

Groups in this outcome

STS Arm (Sodium Thiosulfate Treatment)

Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy. sodium thiosulfate: Given IV examination: Patients undergo audiological assessments periodically

Observation Arm (No Sodium Thiosulfate Treatment)

Patients do not receive sodium thiosulfate. examination: Patients undergo audiological assessments periodically

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
STS Arm (Sodium Thiosulfate Treatment)0
Observation Arm (No Sodium Thiosulfate Treatment)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy. sodium thiosulfate: Given IV examination: Patients undergo audiological assessments periodically
    id
    OG000
    title
    STS Arm (Sodium Thiosulfate Treatment)
  2. description
    Patients do not receive sodium thiosulfate. examination: Patients undergo audiological assessments periodically
    id
    OG001
    title
    Observation Arm (No Sodium Thiosulfate Treatment)
population Description
Data was and never will be collected
reporting Status
POSTED
time Frame
4 weeks after the last dose of cisplatin
title
Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice